In this study, we have demonstrated that IL-12/IL-7/IFN-α mRNA triplet induces much higher anti-tumor potency, compared with that induced by anti-PD-1/PD-L1 therapy in both syngeneic and humanized mouse models. The gene discussed is IL7; the disease is neoplasm.